In the earliest days of the coronavirus vaccine race, (NASDAQ: NVAX) stood out as a potential winner. As a result, investors bet on the company and drove up its share price more than 2,700% back in 2020.

Since then, however, the story hasn't been as bright. Novavax fell behind, launching its vaccine as late as 1 1/2 years after rivals Pfizer and Moderna.

As a result, Novavax lost out on the biggest revenue opportunity, and its shares have been on the decline ever since. Still, Novavax brought in nearly $2 billion in revenue last year, thanks to its vaccine, and aims to launch an updated version for the fall season.

Continue reading

Source Fool.com